Myasthenia gravis (MG) is a disorder of muscle caused by antibodies to the acetylcholine receptors (AChRs) at the motor endplate. It is one of the best characterized diseases because it involves a process, neuromuscular transmission, which is well understood physiologically, and because the target protein has been characterized at the molecular level. Moreover, it fulfils established criteria for autoimmunity, i.e. anti-AChR antibodies can be detected in MG sera, AChR loss at the motor endplate correlates with attached IgG and complement, and Abbreviations used: MG, myasthenia gravis; AChR, acetylcholine receptor; a-BuTx, a-bungarotoxin; EAMG, experimental autoimmune MG; mAb, monoclonal antibody; MIR, main immunogenic region; MHC. major histocompatibility complex; Pen, penicillamine. immunization against purified AChR leads to an animal model of the disease. In addition, plasma exchange, which depletes circulating immunoglobulins, leads to clinical improvement, and a disorder of neuromuscular transmission can be transferred to experimental animals by injection of MG immunoglobulins. This brief account will focus on the nature and possible origins of the autoimmune response. For more detailed reviews see [I, 21. 
The antigen
The nicotinic acetylcholine receptor (AChR) of adult striated muscle is an integral membrane protein consisting of five subunits of stoichiometry a2, B, E and 6, in which the E replaces the embryonic y form. The genes for each of the subunits have now been cloned (see [3] ). The two a-subunits bind a- Volume 19 bungarotoxin (a-HuTx) with high specificity and affinity.
lmmunogenicity of the AChR
High anti-AChR titres can be detected in many species after immunization with less than microgram amounts of AChR in Freund's complete adjuvant. Antibodies against native AChR bind largely to the extracellular surface of the receptor and some will cross-react with the animal's own muscle AChR causing loss of receptor and a defect in neuromuscular transmission. This condition is known as experimental autoimmune myasthenia gravis (EAMG; see [ 21) . Antibodies against recombinant or denatured subunits bind mainly to determinants which are cytoplasmic in vivo or are not accessible in the native conformation. These antibodies seldom cause substantial loss of AChR or clinical weakness in the animals.
Antibodies can also be raised in mice by immunization with native AChR without Freund's adjuvant, suggesting that there is no natural immune tolerance towards this autoantigen [4] . The fine specificity of the antibody-binding sites has been determined by competition with rat monoclonal antibodies, raised against Torpedo and electric eel AChR, which bind to regions on the AChR surface. A high proportion of the rat monoclonal antibodies (mAbs) were found to compete with each other for binding to the 'main immunogenic region' (MIR) on the a-subunits [6]. These anti-MIK mAbs showed some cross-reactivity between different animal species, and several bound to human AChR. On average, about 60% of the antibodies in any MG or EAMG sera were found to compete with the rat anti-MIR mAbs [7] .
Anti-AChR antibodies in MG patients
With mouse mAbs [S, 91 raised against human AChR, only one in ten of the antibodies bound to the MIR of AChR. Other mouse antibodies bound to four partially overlapping regions, one of which was specific for AChR extracted from embryonic or denervated muscle. Mouse mAbs directed at three regions, including the MIR, competed to a similar extent with antibodies from myasthenia gravis patients for binding to AChR [9] .
In spite of knowing the primary sequence of the human AChR a-subunit, it has been difficult to determine the exact amino acid sequences to which the mAbs bind. However, the sequence of a67-76 appears to contribute to the MIR [ 10, 111, and binding of one other mAb has been mapped to ~~1 2 5 -1 4 3
[12]. (see [21) .
T cell epitopes in MG

Different forms of myasthenia
Patients can be divided into three groups on the basis of their different age of onset, thymic pathology and MHC antigens (see Table 1 ). Subtle differences in fine specificity of anti-AChR antibodies have been found in the three main groups [ 151 (see Table 1 ).
Penicillamine (Pen)-induced MG occurs in a proportion, probably about 1 To, of patients undergoing Pen treatment for rheumatoid arthritis. In most Pen-MG patients, myasthenic symptoms regress and anti-AChR antibodies fall after stopping treatment with the drug. The MHC association, Hw35, DRl, is neither typical of MG nor of rheumatoid arthritis ([16] ; Table 1 ). However, the anti-AChK antibodies in Pen-MG do not appear to differ from those in acquired idiopathic MG with regard to light chain, subclass or affinity. Moreover, Pen-MG anti-AChR binds to several regions on the human AChR, probably being most similar to that in young onset patients [ 151 (see Table 1 ).
Origin of the autoimmune response in myasthenia gravis
The aetiological importance of T cells in MG is not yet clear. Although specific T cell responses to recombinant AChR can be detected in MG patients, these can also be found in a proportion of healthy individuals. On the other hand, anti-AChR antibodies are found almost exclusively in MG patients, and there is ample evidence that these antibodies cause the loss of AChR which underlies weakness in this disease [ 1, 21. Therefore, one must ask what antigenic stimulus switches on the production of specific antibodies. There are various theoretical possibilities as listed in Table 2 . There is circumstantial evidence supporting the hypothesis that MG arises from cross-reactivity with an external antigen [ 171 or via an idiotypic network [ 181. However, there is as yet no direct evidence implicating these reactivities in the onset of the disease, and the existence of abnormal levels of anti-idiotypic antibodies in MG has been disputed [ 191. Moreover, the high affinity and specificity of the autoimmune response would tend to argue in favour of a specific antigenic stimulus. AChR can be detected on 'myoid cells in the thymic medulla [20] and an 'AChR-like' epitope has been identified in thymoma tissue [21] . Removal of the thymus, at least in young onset cases, frequently results in clinical improvement and a fall in antiAChR levels. Nevertheless, the role of the thymus is far from clear (see [ 11 for discussion) and it remains a possibility that a low-affinity cross-reaction initiates the disease in susceptible individuals, and that release of complexes of AChR, antibody and complement components from the muscle motor Table 2 Possible origin of autoimmunity in myasthenia gravis
Helper T cell defect Regulatory T cell defect ldiotypic dysregulation Cross-reacting epitope Normal antigen Abnormal antigen Drug-related antigen endplates, or from the thymus, leads to production of the sustained, high-affinity antibody response against AChR which can be detected in the patient's serum.
In Pen-MG the response is clearly related to drug treatment. The existence of other Pen-induced autoimmune diseases argues for a general disturbance of immune tolerance with the specificity of the autoantibodies being at least partly dependent on the individual's MHC antigens [22] . No T cell responses have been reported yet in Pen-MG but the relatively rapid fall in anti-AChR following cessation of the drug suggests that Pen may act at the level of the B cell rather than further back in the chain of events that lead to antibody production.
